ASP/AYTU news ENGLEWOOD, CO / ACCESSWIRE / September 24, 2019 / Aytu BioScience, Inc.
(NASDAQ:AYTU), a specialty pharmaceutical company focused on global
commercialization of novel products addressing significant medical needs,
today announced that Natesto® (testosterone nasal gel) is now on formulary
and covered nationwide by a large, leading national pharmacy benefit manager
(PBM). This PBM contract provides for unrestricted patient access to Natesto,
the only FDA-approved nasally-administered testosterone therapy (TRT), across
the PBM's commercial formularies.
Over thirty million U.S. lives are covered by these prescription plans
nationwide. These 30 million lives are in addition to the previously announced
6 million lives covered under a separate payer contract.
During the 12-month period ending June 2019, the US prescription TRT market
registered 6.9 million prescriptions, generating approximately $1.7 billion in
revenue.
Josh Disbrow, Chief Executive Officer of Aytu BioScience stated, "The addition
of Natesto to this leading national PBM's formulary is a meaningful step in
further building Natesto into a leading brand in the United States. With the
signing of this second payer contract this year, over 36 million patients have
gained access to Natesto in just the past three months. We believe this
expanded coverage will increase physician prescribing of Natesto and enable
improved access to the more than 13 million U.S. men diagnosed with
hypogonadism."
Natesto is the only FDA-approved topically-applied therapy for low
testosterone that does not have a black box warning related to transference of
testosterone to children or women.